Johnson & Johnson Accounts Payable 2010-2025 | JNJ
Johnson & Johnson accounts payable from 2010 to 2025. Accounts payable can be defined as amounts payable to vendors extended as a line of credit for normal business purchases.
- Johnson & Johnson accounts payable for the quarter ending June 30, 2025 were $9.464B, a 6.96% increase year-over-year.
- Johnson & Johnson accounts payable for 2024 were $10.311B, a 7.05% increase from 2023.
- Johnson & Johnson accounts payable for 2023 were $9.632B, a 2.6% decline from 2022.
- Johnson & Johnson accounts payable for 2022 were $9.889B, a 10.55% decline from 2021.
Johnson & Johnson Annual Accounts Payable
(Millions of US $) |
| 2024 |
$10,311 |
| 2023 |
$9,632 |
| 2022 |
$9,889 |
| 2021 |
$11,055 |
| 2020 |
$9,505 |
| 2019 |
$8,544 |
| 2018 |
$7,537 |
| 2017 |
$7,310 |
| 2016 |
$6,918 |
| 2015 |
$6,668 |
| 2014 |
$7,633 |
| 2013 |
$6,266 |
| 2012 |
$5,831 |
| 2011 |
$5,725 |
| 2010 |
$5,623 |
| 2009 |
$5,541 |
Johnson & Johnson Quarterly Accounts Payable
(Millions of US $) |
| 2025-06-30 |
$9,464 |
| 2025-03-31 |
$9,545 |
| 2024-12-31 |
$10,311 |
| 2024-09-30 |
$8,954 |
| 2024-06-30 |
$8,848 |
| 2024-03-31 |
$8,174 |
| 2023-12-31 |
$9,632 |
| 2023-09-30 |
$8,355 |
| 2023-06-30 |
$10,443 |
| 2023-03-31 |
$9,909 |
| 2022-12-31 |
$9,889 |
| 2022-09-30 |
$10,153 |
| 2022-06-30 |
$9,765 |
| 2022-03-31 |
$9,309 |
| 2021-12-31 |
$11,055 |
| 2021-09-30 |
$8,961 |
| 2021-06-30 |
$8,704 |
| 2021-03-31 |
$8,503 |
| 2020-12-31 |
$9,505 |
| 2020-09-30 |
$7,044 |
| 2020-06-30 |
$6,765 |
| 2020-03-31 |
$7,411 |
| 2019-12-31 |
$8,544 |
| 2019-09-30 |
$7,491 |
| 2019-06-30 |
$6,912 |
| 2019-03-31 |
$6,923 |
| 2018-12-31 |
$7,537 |
| 2018-09-30 |
$7,000 |
| 2018-06-30 |
$6,516 |
| 2018-03-31 |
$6,443 |
| 2017-12-31 |
$7,310 |
| 2017-09-30 |
$6,390 |
| 2017-06-30 |
$6,135 |
| 2017-03-31 |
$6,082 |
| 2016-12-31 |
$6,918 |
| 2016-09-30 |
$5,971 |
| 2016-06-30 |
$6,061 |
| 2016-03-31 |
$5,965 |
| 2015-12-31 |
$6,668 |
| 2015-09-30 |
$5,928 |
| 2015-06-30 |
$6,140 |
| 2015-03-31 |
$6,719 |
| 2014-12-31 |
$7,633 |
| 2014-09-30 |
$6,603 |
| 2014-06-30 |
$6,193 |
| 2014-03-31 |
$6,113 |
| 2013-12-31 |
$6,266 |
| 2013-09-30 |
$6,055 |
| 2013-06-30 |
$5,687 |
| 2013-03-31 |
$5,372 |
| 2012-12-31 |
$5,831 |
| 2012-09-30 |
$5,344 |
| 2012-06-30 |
$5,145 |
| 2012-03-31 |
$5,085 |
| 2011-12-31 |
$5,725 |
| 2011-09-30 |
$5,730 |
| 2011-06-30 |
$5,689 |
| 2011-03-31 |
$5,701 |
| 2010-12-31 |
$5,623 |
| 2010-09-30 |
$5,477 |
| 2010-06-30 |
$4,871 |
| 2010-03-31 |
$5,126 |
| 2009-12-31 |
$5,541 |
| 2009-09-30 |
$6,419 |
| 2009-06-30 |
$5,832 |
| 2009-03-31 |
$6,395 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$404.942B |
$88.821B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
